176 related articles for article (PubMed ID: 23018643)
1. γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs.
Gründer C; van Dorp S; Hol S; Drent E; Straetemans T; Heijhuurs S; Scholten K; Scheper W; Sebestyen Z; Martens A; Strong R; Kuball J
Blood; 2012 Dec; 120(26):5153-62. PubMed ID: 23018643
[TBL] [Abstract][Full Text] [Related]
2. CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.
Zhao H; Xi X; Cui L; He W
Cell Mol Immunol; 2012 Mar; 9(2):147-54. PubMed ID: 21909128
[TBL] [Abstract][Full Text] [Related]
3. γ9δ2T cell diversity and the receptor interface with tumor cells.
Vyborova A; Beringer DX; Fasci D; Karaiskaki F; van Diest E; Kramer L; de Haas A; Sanders J; Janssen A; Straetemans T; Olive D; Leusen J; Boutin L; Nedellec S; Schwartz SL; Wester MJ; Lidke KA; Scotet E; Lidke DS; Heck AJ; Sebestyen Z; Kuball J
J Clin Invest; 2020 Sep; 130(9):4637-4651. PubMed ID: 32484803
[TBL] [Abstract][Full Text] [Related]
4. Tumor-killing γδ-TCRs take center stage.
Moser B
Blood; 2012 Dec; 120(26):5093-4. PubMed ID: 23258897
[No Abstract] [Full Text] [Related]
5. Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Gade TP; Hassen W; Santos E; Gunset G; Saudemont A; Gong MC; Brentjens R; Zhong XS; Stephan M; Stefanski J; Lyddane C; Osborne JR; Buchanan IM; Hall SJ; Heston WD; Rivière I; Larson SM; Koutcher JA; Sadelain M
Cancer Res; 2005 Oct; 65(19):9080-8. PubMed ID: 16204083
[TBL] [Abstract][Full Text] [Related]
6. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
7. TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.
Spranger S; Jeremias I; Wilde S; Leisegang M; Stärck L; Mosetter B; Uckert W; Heemskerk MH; Schendel DJ; Frankenberger B
Blood; 2012 Apr; 119(15):3440-9. PubMed ID: 22371883
[TBL] [Abstract][Full Text] [Related]
8. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
9. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Zhao Y; Moon E; Carpenito C; Paulos CM; Liu X; Brennan AL; Chew A; Carroll RG; Scholler J; Levine BL; Albelda SM; June CH
Cancer Res; 2010 Nov; 70(22):9053-61. PubMed ID: 20926399
[TBL] [Abstract][Full Text] [Related]
10. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
11. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
12. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Straetemans T; Kierkels GJJ; Doorn R; Jansen K; Heijhuurs S; Dos Santos JM; van Muyden ADD; Vie H; Clemenceau B; Raymakers R; de Witte M; Sebestyén Z; Kuball J
Front Immunol; 2018; 9():1062. PubMed ID: 29899740
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effector functions of T cells are dependent on in vivo priming and restricted T-cell receptor expression.
Lüking C; Kronenberger K; Frankenberger B; Nössner E; Röcken M; Mocikat R
Int J Cancer; 2008 May; 122(10):2280-5. PubMed ID: 18224683
[TBL] [Abstract][Full Text] [Related]
14. Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells.
Liu Z; Noh HS; Chen J; Kim JH; Falo LD; You Z
J Immunol; 2008 Sep; 181(6):4363-70. PubMed ID: 18768895
[TBL] [Abstract][Full Text] [Related]
15. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26
Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X
Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776
[TBL] [Abstract][Full Text] [Related]
16. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
17. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.
Beck BH; Kim HG; Kim H; Samuel S; Liu Z; Shrestha R; Haines H; Zinn K; Lopez RD
Breast Cancer Res Treat; 2010 Jul; 122(1):135-44. PubMed ID: 19763820
[TBL] [Abstract][Full Text] [Related]
18. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
[TBL] [Abstract][Full Text] [Related]
20. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
